Molecular Biological Investigation in Chronic Myelogenous Leukemia Patients Undergoing Interferon Therapy

1988 ◽  
pp. 27-33
Author(s):  
B. Opalka ◽  
U. Wandl ◽  
O. Kloke ◽  
J. Koppe ◽  
N. Niederle
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Interferon Therapy ◽  
Myelogenous Leukemia ◽  
Biological Investigation

Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia

Cancer ◽  
1999 ◽  
Vol 85 (12) ◽  
pp. 2583-2588 ◽  
Author(s):  
Farhad Ravandi-Kashani ◽  
Jorge Cortes ◽  
Moshe Talpaz ◽  
Hagop M. Kantarjian
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Thrombotic Microangiopathy ◽  
Interferon Therapy ◽  
Myelogenous Leukemia

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

Cancer ◽  
1991 ◽  
Vol 68 (10) ◽  
pp. 2125-2130 ◽  
Author(s):  
M. Talpaz ◽  
R. Kurzrock ◽  
H. Kantarjian ◽  
J. Rothberg ◽  
S. Saks ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Phase Ii ◽  
Interferon Therapy ◽  
Phase Ii Study ◽  
Gamma Interferon ◽  
Myelogenous Leukemia

scholarly journals Clinical investigation of human alpha interferon in chronic myelogenous leukemia

Blood ◽  
1987 ◽  
Vol 69 (5) ◽  
pp. 1280-1288 ◽  
Author(s):  
M Talpaz ◽  
HM Kantarjian ◽  
KB McCredie ◽  
MJ Keating ◽  
J Trujillo ◽  
...  
Keyword(s):  
Survival Rate ◽  
Chronic Myelogenous Leukemia ◽  
Interferon Therapy ◽  
Clinical Investigation ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Human Leukocyte ◽  
Myelogenous Leukemia ◽  
Alpha Interferon ◽  
Risk Category

Abstract Fifty-one patients with previously untreated or minimally treated chronic myelogenous leukemia in chronic phase received human alpha interferon 3 to 9 X 10(6) units intramuscularly (IM) daily until complete hematologic remission, then at doses ranging from 3 X 10(6) units every other day to 9 X 10(6) units daily. Forty-one (80%) patients achieved a hematologic response, 36 (71%) of them attaining a complete hematologic remission with normal peripheral WBC and differential counts. Responding patients showed continuous but slow normalization of several other blood and marrow parameters including platelet counts, serum lactic dehydrogenase and B12 levels, and marrow cellularity and maturation index. Suppression of the Philadelphia chromosome on serial cytogenetic studies of marrow metaphases was documented in 20 of the 36 patients who achieved complete hematologic remission (56%; 39% of total group), eight of whom (22%) had a decrease of the Philadelphia chromosome-positive metaphases to less than 35%. These changes were persistent for 6 months or longer in 18 patients, seven of whom had continuous suppression of the Philadelphia chromosome to less than 90% for a median of 30+ months (range 21+ to 39+ months). After a median follow-up period of 37 months, 25 patients remain in continued disease control with interferon therapy. The projected 3-year survival rate is 76%, with a yearly death rate of 6%, 9%, and 9% in the first 3 years. Response, Philadelphia chromosome suppression, and survival were significantly better among patients in the low-risk category compared to intermediate- and high-risk categories, as defined by a multivariate analysis-derived prognostic model. The projected 3- year survival rate was 94% for patients who achieved a complete hematologic remission on interferon therapy and 45% for those who did not. Thirteen patients have developed blastic crisis, six with lymphoid and three with undifferentiated morphology. We conclude that human leukocyte alpha interferon effectively controls chronic myeloid leukemia and allows reappearance of diploid hemopoietic cells in some patients.

Interferon therapy in chronic myelogenous leukemia

2004 ◽  
Vol 18 (3) ◽  
pp. 585-603 ◽  
Author(s):  
François Guilhot ◽  
Lydia Roy ◽  
Joëlle Guilhot ◽  
Fredéric Millot
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Interferon Therapy ◽  
Myelogenous Leukemia

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.

1996 ◽  
Vol 14 (1) ◽  
pp. 196-203 ◽  
Author(s):  
A Majlis ◽  
T L Smith ◽  
M Talpaz ◽  
S O'Brien ◽  
M B Rios ◽  
...  
Keyword(s):  
Survival Time ◽  
Chronic Myelogenous Leukemia ◽  
Median Survival ◽  
Median Survival Time ◽  
Interferon Therapy ◽  
Clonal Evolution ◽  
Prognostic Significance ◽  
Risk Groups ◽  
Myelogenous Leukemia ◽  
Chromosome 17

PURPOSE To describe the incidence and significance of clonal evolution patterns. PATIENTS AND METHODS We analyzed 264 patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who developed clonal evolution between 1967 and 1993. RESULTS The median survival time following clonal evolution was 19 months. Factors associated with worse survival (P < .01) were as follows: chromosome 17 abnormality or chromosomal translocations other than Ph, high percentage of abnormal metaphases, longer time to clonal evolution, and presence of other accelerated-phase features. A recursive partitioning technique (CART) identified different risk groups. The best group (37 patients; no chromosome 17 abnormality, abnormal metaphases < 16%, and interval to clonal evolution < or = 24 months) had an estimated median survival time of 54 months. The worst two groups included 27 patients with chromosome 17 abnormalities and > or = 36% abnormal metaphases (estimated median survival time, 6 months), and 22 patients with other accelerated features and > or = 16% abnormal metaphases (estimated median survival time, 7 months). The intermediate group had an estimated median survival time that ranged from 13 to 24 months. Prior interferon therapy evaluated within risk groups showed a significant survival advantage only in the intermediate-risk group. A multivariate analysis showed similar results, and identified the following independent poor prognostic variables: chromosome 17 abnormality, percentage of abnormal metaphases (cutoff, 24%), longer time to clonal evolution (cutoff, 24 months), other accelerated-phase features, and no prior interferon therapy. Patients with none, one, two, three, or more of the first four features had median survivals times of 51, 24, 14, and 7 months, respectively. CONCLUSION The prognostic significance of clonal evolution in CML is not uniform and is related to the specific abnormality, time to its development, its predominance in metaphases, and the presence of other accelerated features, and it may be modified by specific therapies.

scholarly journals Clinical investigation of human alpha interferon in chronic myelogenous leukemia

Blood ◽  
1987 ◽  
Vol 69 (5) ◽  
pp. 1280-1288 ◽  
Author(s):  
M Talpaz ◽  
HM Kantarjian ◽  
KB McCredie ◽  
MJ Keating ◽  
J Trujillo ◽  
...  
Keyword(s):  
Survival Rate ◽  
Chronic Myelogenous Leukemia ◽  
Interferon Therapy ◽  
Clinical Investigation ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Human Leukocyte ◽  
Myelogenous Leukemia ◽  
Alpha Interferon ◽  
Risk Category

Fifty-one patients with previously untreated or minimally treated chronic myelogenous leukemia in chronic phase received human alpha interferon 3 to 9 X 10(6) units intramuscularly (IM) daily until complete hematologic remission, then at doses ranging from 3 X 10(6) units every other day to 9 X 10(6) units daily. Forty-one (80%) patients achieved a hematologic response, 36 (71%) of them attaining a complete hematologic remission with normal peripheral WBC and differential counts. Responding patients showed continuous but slow normalization of several other blood and marrow parameters including platelet counts, serum lactic dehydrogenase and B12 levels, and marrow cellularity and maturation index. Suppression of the Philadelphia chromosome on serial cytogenetic studies of marrow metaphases was documented in 20 of the 36 patients who achieved complete hematologic remission (56%; 39% of total group), eight of whom (22%) had a decrease of the Philadelphia chromosome-positive metaphases to less than 35%. These changes were persistent for 6 months or longer in 18 patients, seven of whom had continuous suppression of the Philadelphia chromosome to less than 90% for a median of 30+ months (range 21+ to 39+ months). After a median follow-up period of 37 months, 25 patients remain in continued disease control with interferon therapy. The projected 3-year survival rate is 76%, with a yearly death rate of 6%, 9%, and 9% in the first 3 years. Response, Philadelphia chromosome suppression, and survival were significantly better among patients in the low-risk category compared to intermediate- and high-risk categories, as defined by a multivariate analysis-derived prognostic model. The projected 3- year survival rate was 94% for patients who achieved a complete hematologic remission on interferon therapy and 45% for those who did not. Thirteen patients have developed blastic crisis, six with lymphoid and three with undifferentiated morphology. We conclude that human leukocyte alpha interferon effectively controls chronic myeloid leukemia and allows reappearance of diploid hemopoietic cells in some patients.

35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α-interferon therapy

1992 ◽  
Vol 41 (2) ◽  
pp. 141-141 ◽  
Author(s):  
Nilesh D. Mehta ◽  
Arthur L. Hooberman ◽  
Everett E. Vokes ◽  
Scott Neeley ◽  
Scott Cotler
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Chronic Myelogenous Leukemia ◽  
Lupus Erythematosus ◽  
Interferon Therapy ◽  
Myelogenous Leukemia ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document